A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

Stopped early · Phase 1

Conditions studied: Non-Small Cell Lung Cancer

In brief

The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous Non-Small Cell Lung Cancer.

Key facts

Study ID

NCT02309892

Run by

Helix BioPharma Corporation

People needed

14

Starts

2015-04-20

Expected to finish

2019-09-20

Last updated by the study team

2024-06-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University Hospitals Case Medical Center — Cleveland, Ohio, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.